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Back in August, the silicon equipment
manufacturers association SEMI (whose
co-founder, Bill Hugle, sadly died in
October) quietly slipped SiGe, GaAs and
InP under its arm and into its future silicon
road map, slotting these compounds into
the new wireless communications chapter.
SEMI might have made the first move, but
it is now followed in Europe by silicon's
premiere research laboratory IMEC. For
many in the compound industry, IMEC
probably has a low profile. Based in
Leuven, Belgium, IMEC was established in
1984 by the state government as a non-
profit organisation with an initial invest-
ment of 63m and a staff of 70. Working
quietly through strategic partnerships on
all aspects in the development of silicon,
chips and memory, initially with European
fabs and equipment manufacturers, it has
now grown to offices in California and
Shanghai and  Japanese representation. 
It is the largest independent silicon R&D
centre in Europe, and with its budget of
145m owes only 34m to a government
grant. The staff number 1,300 and the col-
laborators around 500.
At its October annual meeting to discuss
developments and look at the future,
IMEC president and CEO, Gilbert Declerck
announced that the mission for sub45nm
CMOS would involve advanced materials,
process steps and modules as well as
novel device concepts ‘beyond classical
CMOS.’  Silicon’s potential brick wall is
now causing IMEC programmes to draw
on Germanium CMOS based devices
(SiGe); epitaxial growth of AlGaN/GaN
HEMT amplifiers as well as InGaP and
GaAs (for the photovoltaic needs of the
European Space Agency).
What's so interesting is there are two dis-
tinct levels of activity.  The main action is
seen as IMEC’s first five core partners in
sub45nm research.  Infineon, Intel, Philips,
Samsung and STMicroelectronics are co-
funding and participating in programmes
“ranging from 1.5m to 500,000-
600,000.”  They  may be joined by
another three to five players. The major
activity will move from the 200mm wafer
line to the new 300mm line in rising new
buildings to be completed in 2004 (build-
ing and infra-structure cost 84m and
several 100m worth of equipment).
Meanwhile the modest future brick-wall
beaters, with very little pomp have had
their MOVPE equipment, formerly located
at Ghent, moved into laboratories at
IMEC's Leuven site, close to the 200mm
line and compound work goes on. 
It’s a breathtaking thought - small sub 6”
wafer production in the shadow of the
200mm and piazza size 300mm wafers.
Watch out for IMEC’s compound growth.  
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growth
Editorial
Subscription enquiries, orders and payments:
For customers residing in the Americas (North, South
and Central America)
Elsevier, Customer Support Department, PO Box 945,New
York NY 10010, USA
Tel: +1 212-633-3730 [Toll Free number for North American
customers: 1-800-4ES-INFO (437-4636)]  
Fax: +1 212-633-3680, E-mail: usinfo-f@elsevier.com
For customers in the Rest of the World:
Elsevier, Customer Support Dept. PO Box 211, 
1000 AE Amsterdam, The Netherlands
Tel: +31 20-4853757, Fax: +31 20-4853432
E-mail: nlinfo-f@elsevier.nl
Subscriptions: Annual subscription (nine issues) US$311/
278.00/¥37,000. Price valid to end of 2003 and includes
airmail delivery in Europe and airspeeded delivery elsewhere.
A member of the Reed Elsevier plc group 
III-Vs Review is published nine times a year. Periodicals post-
age is paid at Rahway, NJ 07065. Postmaster send address
corrections to: III-Vs Review, 365 Blair Rd, Avenel, NJ 07001.
The opinions expressed by individuals in this 
publication are not necessarily those of Elsevier, who
shall not be held responsible for them. All trademarks
acknowledged.
Printed by: The Manson Group Ltd, St Albans, UK.  
Journal Number: 02076 ISSN 0961-1290
Colbrite Gloss is manufactured from ECF pulp produced
from renewable forest resources. ECF pulp is pulp bleached
without using elemental chlorine
© 2003 Elsevier Ltd. All rights reserved. This journal and the
individual contributions contained in it are protected under
copyright by Elsevier Ltd, and the following terms and 
conditions apply to their use:
Photocopying
Single photocopies of single articles may be made for per-
sonal use as allowed by national copyright laws. Permission
of the publisher and payment of a fee is required for all
other photocopying, including multiple or systematic copy-
ing, copying for advertising or promotional purposes, resale,
and all forms of document delivery. Special rates are avail-
able for educational institutions that wish to make photo-
copies for non-profit educational classroom use.
Permissions may be sought directly from Elsevier Rights &
Permissions Department, PO Box 800, Oxford OX5 1DX, UK;
tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail:
permissions@elsevier.co.uk. You may also contact Rights &
Permissions directly through Elsevier’s home page
(http://www.elsevier.nl), selecting first ‘Customer Support’,
then ‘General Information’, then ‘Permissions Query Form’.
In the USA, users may clear permissions and make payments
through the Copyright Clearance Center, Inc, 222 Rosewood
Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1
978 7504744, and in the UK through the Copyright
Licensing Agency Rapid Clearance Service (CLARCS), 90
Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0)20
7436 5931; fax: +44 (0)20 7436 3986. Other countries may
have a local reprographic rights agency for payments.
Derivative Works
Subscribers may reproduce tables of contents or prepare lists
of articles including abstracts for internal circulation within
their institutions. Permission of the publisher is required for
resale or distribution outside the institution. 
Permission of the publisher is required for all other derivative
works, including compilations and translations. 
Electronic Storage or Usage
Permission of the publisher is required to store or use elec-
tronically any material contained in this journal, including
any article or part of an article. Contact the publisher at the
address indicated. 
Except as outlined above, no part of this publication may be
reproduced, stored in a retrieval system or transmitted in any
form or by any means, electronic, mechanical, photocopy-
ing, recording or otherwise, without prior written permission
of the publisher.
Address permissions requests to: Elsevier Rights &
Permissions Department, at the mail, fax and e-mail 
addresses noted above.
Notice
No responsibility is assumed by the Publisher for any injury
and/or damage to persons or property as a matter of prod-
ucts liability, negligence or otherwise, or from any use or
operation of any methods, products, instructions or ideas
contained in the material herein. Because of rapid advances
in the medical sciences, in particular, independent verifica-
tion of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to
ethical (medical) standards, inclusion in this publication does
not constitute a guarantee or endorsement of the quality 
or value of such product or of the claims made of it by its
manufacturer. 
Free circulation enquiries
Tower Publishing, Tower House, Sovereign Park, Market
Harborough, Leicestershire, LE16 9EF. 
III-Vs Review is a member of BPA
International, the leading world 
auditor of business publications.
pp2-3.qxd  24/10/2003  15:12  Page 2
